DR. LAL PATHLABS LTD.
NSE : LALPATHLABBSE : 539524ISIN
CODE : INE600L01024Industry : Hospital & Healthcare ServicesHouse
: Arvind Lal
BSE2535.90-13.4 (-0.53 % )
PREV CLOSE (Rs.) 2549.30
OPEN PRICE (Rs.) 2558.95
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1923
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE2535.65 -13.6 (-0.53 % )
PREV CLOSE(Rs.) 2549.25
OPEN PRICE (Rs.) 2555.00
BID PRICE (QTY) 2535.65 (81 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 20022
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 03-May-2024 | Dr. Lal PathLabs informs about board meeting | <p style="text-align: justify;">Dr. Lal PathLabs has informed that a meeting of the Board of Directors is scheduled to be held on Friday, May 10, 2024 to consider and approve the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial year ended March 31, 2024 and to consider recommending Final Dividend, if any, on the Equity Shares of the Company for the Financial Year ended March 31, 2024. Further, in continuation to its letter dated March 26, 2024 and in line with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, the Trading Window for dealing in Securities of the Company is closed and shall re-open after 48 hours from the declaration of the aforesaid Financial Results.</p><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 26-Mar-2024 | Dr. Lal PathLabs informs about closure of trading window | <p style="text-align: justify;">Dr. Lal PathLabs has informed that as per the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, the Trading Window for dealing in Securities of the Company shall be closed from April 01, 2024 and would be re-opened after 48 hours from the date of announcement/ declaration of Audited Financial Results for the Quarter and Financial Year ending March 31, 2024.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p><div><br></div> |
| 18-Mar-2024 | Board Meeting Outcome for Appointment Of Chief Executive Officer (Key Managerial Personnel) | Based on recommendations of Nomination & Remuneration Committee, the Board of Directors in their meeting held today i.e., March 17, 2024, inter-alia, approved the re-designation of Mr. Shankha Banerjee by appointing him as Chief Executive Officer (CEO) and Key Managerial Personnel (KMP) with effect from May 21, 2024 |
| 18-Mar-2024 | Dr. Lal PathLabs informs about outcome of committee meet | <p style="text-align: justify;">Dr. Lal PathLabs has informed that, based on recommendations of Nomination & Remuneration Committee, the Board of Directors in their meeting held on March 17, 2024, approved the re-designation of Shankha Banerjee by appointing him as Chief Executive Officer (CEO) and Key Managerial Personnel (KMP) with effect from May 21, 2024. The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and other applicable circulars, if any, is enclosed as ‘Annexure A'. Further, in view of above appointment and pursuant to Regulation 30(5) of Listing Regulations, the company has enclosed the details of the authorized persons for the purpose of determining materiality of any event or information, which shall be effective from May 21, 2024. Based on the decision of the above-named officials, the Compliance Officer shall be responsible for making disclosure to the Stock Exchange(s) and his contact details are also enclosed. The Board Meeting commenced at 11:00 am (IST) and concluded at 11:18 am (IST).</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p><div><br></div><div><br></div> |
| 01-Feb-2024 | Dr. Lal PathLabs informs about earnings presentation | <p style="text-align: justify;">Dr. Lal PathLabs has informed that it attached a copy of Company's Q3 & 9M FY24 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2023, as approved by the Board of Directors in their meeting held on February 01, 2024.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 25-Jan-2024 | Dr. Lal PathLabs informs about board meeting | <p style="text-align: justify;">Dr. Lal PathLabs has informed that a meeting of the Board of Directors is scheduled to be held on Thursday, February 01, 2024 to consider and approve the Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Nine Months ended December 31, 2023 and to consider the proposal of declaration of 2nd interim dividend, if any, on the equity shares of the Company for the Financial Year 2023-24. Further, in continuation to its letter dated December 26, 2023 and in line with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, the Trading Window for dealing in Securities of the Company is closed and shall re-open after 48 hours from the declaration of the aforesaid Financial Results.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 25-Jan-2024 | Dr. Lal PathLabs informs about closure of trading window | <div style="text-align: justify;">Dr. Lal PathLabs has informed that a meeting of the Board of Directors is scheduled to be held on Thursday, February 01, 2024 to consider and approve the Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Nine Months ended December 31, 2023 and to consider the proposal of declaration of 2nd interim dividend, if any, on the equity shares of the Company for the Financial Year 2023-24. Further, in continuation to letter dated December 26, 2023 and in line with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, the Trading Window for dealing in Securities of the Company is closed and shall re-open after 48 hours from the declaration of the aforesaid Financial Results.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 25-Jan-2024 | Dr. Lal PathLabs informs about conference call | <p style="text-align: justify;">Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Dr. Lal PathLabs has informed that it enclosed the invite of the Conference Call for Investors/ Analysts to be held on Thursday, February 01, 2024 at 5:00 pm (IST) to discuss the financial and operating performance for Q3 & 9M FY24.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.<br><br></p><div style="text-align: justify;"><br></div> |
| 17-Nov-2023 | Dr. Lal PathLabs informs about allotment of equity shares under ESOP | <div><p style="text-align: justify;">Dr. Lal PathLabs has informed that the Board of Directors through Circular Resolution approved allotment of 8,000 Equity Shares under the ESOP 2010 Plan of the Company, on November 17, 2023. Pursuant to the above allotment, the Paid-up Equity Share Capital of the Company increased to INR 83,47,78,520 divided into 8,34,77,852 Equity Shares of INR 10 each.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p></div><div style="text-align: justify;"><br></div> |
| 15-Sep-2023 | Dr. Lal PathLabs informs about analyst meet | <p style="text-align: justify;">Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that it enclosed the details of proposed schedule of Analyst/ Institutional Investor meeting(s). </p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
